Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

Front Med (Lausanne)

Rheumatology Division and Instituto de Investigación Sanitaria del Principado de Asturias Translational Immunology Section, Hospital Universitario Central de Asturias, Oviedo, Spain.

Published: December 2021

Non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of treatment for spondyloarthritides (SpA), a group of entities with common clinical and pathophysiological aspects, but also with differential features. Although NSAIDs provide significant symptomatic relief, especially for joint pain and morning stiffness, their role in achieving and maintaining the treatment goals advocated by the treat to target strategy in SpA is not entirely clear. These agents can induce changes in the composition of the intestinal microbiota, also favoring an alteration of the barrier function in the gut epithelium. All of this, favored by a pre-disposing genetic background, could activate a specific type of aberrant immune response in the gut lamina propria, also known as type-3 immunity. This article offers a perspective on how NSAIDs, despite their undeniable value in the short-term SpA treatment, could hinder the achievement of medium and long-term treatment goals by compromising the barrier function of the gut mucosa and potentially altering the composition of the gut microbiota.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739512PMC
http://dx.doi.org/10.3389/fmed.2021.817884DOI Listing

Publication Analysis

Top Keywords

treatment goals
12
barrier function
8
function gut
8
nsaids
4
nsaids treatment
4
goals axial
4
axial spondyloarthritis
4
spondyloarthritis story
4
story dysbiosis
4
dysbiosis matter
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!